Nothing Special   »   [go: up one dir, main page]

DK3215530T3 - Forbedrede il-6 antistoffer - Google Patents

Forbedrede il-6 antistoffer Download PDF

Info

Publication number
DK3215530T3
DK3215530T3 DK15797538T DK15797538T DK3215530T3 DK 3215530 T3 DK3215530 T3 DK 3215530T3 DK 15797538 T DK15797538 T DK 15797538T DK 15797538 T DK15797538 T DK 15797538T DK 3215530 T3 DK3215530 T3 DK 3215530T3
Authority
DK
Denmark
Prior art keywords
antibodies
improved
Prior art date
Application number
DK15797538T
Other languages
English (en)
Inventor
Alison Tisdale
Eric Steven Furfine
Grigorios Zarbis-Papastoitsis
Michael March Schmidt
Original Assignee
Sesen Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sesen Bio Inc filed Critical Sesen Bio Inc
Application granted granted Critical
Publication of DK3215530T3 publication Critical patent/DK3215530T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK15797538T 2014-11-07 2015-11-06 Forbedrede il-6 antistoffer DK3215530T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462077105P 2014-11-07 2014-11-07
US201462087448P 2014-12-04 2014-12-04
US201562247705P 2015-10-28 2015-10-28
PCT/US2015/059532 WO2016073890A1 (en) 2014-11-07 2015-11-06 Improved il-6 antibodies

Publications (1)

Publication Number Publication Date
DK3215530T3 true DK3215530T3 (da) 2019-11-25

Family

ID=54602042

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15797538T DK3215530T3 (da) 2014-11-07 2015-11-06 Forbedrede il-6 antistoffer

Country Status (30)

Country Link
US (3) US11142571B2 (da)
EP (3) EP4268843A3 (da)
JP (1) JP6594438B2 (da)
KR (2) KR102636726B1 (da)
CN (1) CN107249631B (da)
AU (1) AU2015342882B2 (da)
CA (1) CA2965689C (da)
CL (1) CL2017001135A1 (da)
CO (1) CO2017005404A2 (da)
CR (1) CR20170231A (da)
DK (1) DK3215530T3 (da)
EA (1) EA035199B1 (da)
ES (1) ES2756275T3 (da)
HR (1) HRP20191945T1 (da)
HU (1) HUE046181T2 (da)
IL (1) IL251858B (da)
MA (1) MA51554A (da)
MX (2) MX385206B (da)
MY (1) MY185114A (da)
PE (1) PE20171107A1 (da)
PH (1) PH12017500809B1 (da)
PL (1) PL3215530T3 (da)
PT (1) PT3215530T (da)
RS (1) RS59805B1 (da)
SA (1) SA517381458B1 (da)
SG (2) SG11201703574VA (da)
SI (1) SI3215530T1 (da)
UA (1) UA122673C2 (da)
WO (1) WO2016073890A1 (da)
ZA (1) ZA201702985B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI748962B (zh) 2015-09-23 2021-12-11 美商建南德克公司 抗ｖｅｇｆ抗體之最佳化變異體
CA3012350A1 (en) * 2016-02-23 2017-08-31 Sesen Bio, Inc. Il-6 antagonist formulations and uses thereof
EA201991207A1 (ru) * 2016-12-19 2019-12-30 Гленмарк Фармасьютикалс С.А. Новые агонисты tnfr и их применение
AR111190A1 (es) 2017-03-22 2019-06-12 Genentech Inc Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados
TWI839327B (zh) 2017-03-22 2024-04-21 美商建南德克公司 用於治療眼部病症之最佳化之抗體組合物
CN109867723B (zh) * 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途
TW202144410A (zh) 2020-03-13 2021-12-01 美商建南德克公司 抗介白素－３３抗體及其用途
TW202144419A (zh) 2020-03-24 2021-12-01 美商建南德克公司 Ｔｉｅ２結合劑及其使用方法
EP4228702A1 (en) 2020-10-15 2023-08-23 F. Hoffmann-La Roche AG Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery
CN116554298A (zh) * 2022-02-25 2023-08-08 南京工业大学 一种强化细菌卷曲菌毛提高人表皮生长因子分泌生产效率的方法
CN115343483B (zh) * 2022-08-12 2024-11-26 苏州邦器生物技术有限公司 一种自身免疫性糖尿病检测用试剂盒及其制备方法
CN120112551A (zh) * 2022-10-24 2025-06-06 豪夫迈·罗氏有限公司 预测对il-6拮抗剂的反应

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
EP1279731B1 (en) 1991-03-01 2007-05-30 Dyax Corporation Process for the development of binding mini-proteins
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2734739B1 (fr) 1995-06-01 1997-07-11 Gec Alsthom Stein Ind Dispositif de surveillance d'un broyeur a boulets
TW311927B (da) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
EP0795743A3 (en) 1996-03-15 1998-02-25 Japan Tobacco Inc. Method and apparatus for infra-red moisture measurement
US5839430A (en) 1996-04-26 1998-11-24 Cama; Joseph Combination inhaler and peak flow rate meter
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US6358058B1 (en) 1998-01-30 2002-03-19 1263152 Ontario Inc. Aerosol dispensing inhaler training device
JP4562286B2 (ja) 1998-12-10 2010-10-13 ブリストル−マイヤーズ スクウィブ カンパニー 抗体模倣物および他の結合タンパク質のタンパク質骨格
KR20020047132A (ko) 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
JP4369662B2 (ja) 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
CA2466034C (en) 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
EP1503731A1 (en) 2002-05-07 2005-02-09 Control Delivery Systems, Inc. Processes for forming a drug delivery device
WO2004045507A2 (en) * 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
KR20070001932A (ko) 2003-12-23 2007-01-04 리나트 뉴로사이언스 코퍼레이션 작용물질 항 티알케이씨 항체 및 그의 사용 방법
BR122018016031B8 (pt) 2004-08-04 2021-07-27 Applied Molecular Evolution Inc processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
ATE550353T1 (de) 2005-12-30 2012-04-15 Merck Patent Gmbh Die bindung von mit il-6ralpha komplexiertem il-6 an gp130 verhindernde anti-il-6-antikörper
JP2009529339A (ja) 2006-03-13 2009-08-20 アブリンクス エン．ヴェー． Ｉｌ−６を標的とするアミノ酸配列およびそれを含みｉｌ−６介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド
DK2021463T3 (da) 2006-05-19 2017-01-16 Alder Biopharmaceuticals Inc Dyrkningsfremgangsmåde til at opnå en klonet population af antigen-specifikke B-celler
NZ597767A (en) * 2007-05-21 2013-06-28 Bristol Myers Squibb Co Antibodies to IL-6 and use thereof
KR20160005378A (ko) 2007-09-14 2016-01-14 사노피 파스테르 바이오로직스, 엘엘씨 클로스트리듐 디피실리 톡소이드 ａ 및 ｂ를 포함하는 약학적 조성물
BRPI0820387A2 (pt) 2007-11-21 2015-05-26 Amgen Inc Agentes de ligação de wise e epítopos
US20100187601A1 (en) 2007-12-12 2010-07-29 Fujio Masuoka Semiconductor device
CN104188911A (zh) 2008-01-15 2014-12-10 Abbvie德国有限责任两合公司 粉末状蛋白质组合物及其制备方法
WO2010015608A1 (en) 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
PL2324930T3 (pl) 2008-09-12 2013-02-28 Kdf Co Ltd Urządzenie wytryskujące wodę
US20120005773A1 (en) 2008-10-01 2012-01-05 Aasen Eric D Transgenic plants with enhanced agronomic traits
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
CA2744055A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
WO2010088444A1 (en) 2009-01-29 2010-08-05 Medimmune, Llc Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
ES2704223T3 (es) 2010-07-12 2019-03-15 Pfizer Healthcare Ireland Conjugados de anticuerpos multifuncionales
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
AU2013334740A1 (en) 2012-10-25 2015-04-02 Medimmune, Llc Stable, low viscosity antibody formulation
AU2013342163B2 (en) * 2012-11-08 2018-08-16 F. Hoffmann-La Roche Ltd IL-6 antagonists and uses thereof
HK1223319A1 (zh) 2013-07-12 2017-07-28 Iveric Bio, Inc. 用於治療或預防眼科病的方法
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention

Also Published As

Publication number Publication date
AU2015342882A1 (en) 2017-05-18
US20190194312A1 (en) 2019-06-27
WO2016073890A1 (en) 2016-05-12
MY185114A (en) 2021-04-30
IL251858B (en) 2022-09-01
US20250059270A1 (en) 2025-02-20
JP2017535285A (ja) 2017-11-30
ES2756275T9 (es) 2020-10-29
HUE046181T2 (hu) 2020-02-28
KR20170077196A (ko) 2017-07-05
PE20171107A1 (es) 2017-08-07
KR102636726B1 (ko) 2024-02-13
EA035199B1 (ru) 2020-05-14
MA51554A (fr) 2020-11-18
KR20240023450A (ko) 2024-02-21
PT3215530T (pt) 2019-11-21
SG10202103420PA (en) 2021-05-28
HK1244008A1 (en) 2018-07-27
CN107249631A (zh) 2017-10-13
AU2015342882B2 (en) 2021-05-20
MX2017005992A (es) 2017-09-15
RS59805B1 (sr) 2020-02-28
ES2756275T3 (es) 2020-04-27
CN107249631B (zh) 2021-11-23
US11142571B2 (en) 2021-10-12
CR20170231A (es) 2017-09-25
IL251858A0 (en) 2017-06-29
EP3215530B1 (en) 2019-08-21
EA201791005A1 (ru) 2017-09-29
KR102770849B1 (ko) 2025-02-20
JP6594438B2 (ja) 2019-10-23
EP3632931A1 (en) 2020-04-08
ZA201702985B (en) 2019-10-30
MX385206B (es) 2025-03-14
SI3215530T1 (sl) 2020-02-28
SG11201703574VA (en) 2017-05-30
MX2021008663A (es) 2021-08-19
UA122673C2 (uk) 2020-12-28
EP3215530A1 (en) 2017-09-13
BR112017008672A2 (pt) 2018-03-20
CA2965689C (en) 2022-03-22
EP4268843A2 (en) 2023-11-01
US20220169719A1 (en) 2022-06-02
EP4268843A3 (en) 2023-12-27
PH12017500809A1 (en) 2017-10-02
EP3215530B9 (en) 2020-09-09
NZ731090A (en) 2024-03-22
CL2017001135A1 (es) 2017-12-15
CO2017005404A2 (es) 2017-10-31
PH12017500809B1 (en) 2023-09-20
SA517381458B1 (ar) 2020-07-09
CA2965689A1 (en) 2016-05-12
PL3215530T3 (pl) 2020-05-18
HRP20191945T1 (hr) 2020-01-24

Similar Documents

Publication Publication Date Title
NL301117I1 (nl) trastuzumab deruxtecan
DK3344654T3 (da) Anti-lag-3-antistoffer
SI3354729T1 (sl) Protitelesa anti-garp
DK3126395T3 (da) Multispecifikke antistoffer
DK3160994T3 (da) Multispecifikke antigenbindende proteiner
DK3556777T3 (da) Multispecifikke antistofkonstrukter
DK3183272T3 (da) Asymmetriske multispecifikke antistoffer
HUE060878T2 (hu) Anti-transztiretin antitestek
CL2016001742A1 (es) Anticuerpos anti-baff novedosos
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
DK3157559T3 (da) Anti-axl-antistoffer
DK3250593T3 (da) Anti-transthyretin-antistoffer
DK3215530T3 (da) Forbedrede il-6 antistoffer
LT3092003T (lt) Naujas anti-netrino-1 antikūnas
HUE054148T2 (hu) Anti-ORAI1 antitest
LT3126391T (lt) Hpa-1a antikūnai
LT3628731T (lt) Naujas antipresepsino antikūnas
DK3484921T3 (da) Anti-IL-22R antistoffer
HRP20182029T1 (hr) Uti-fuzijski proteini
ITUB20155097A1 (it) Anticorpi umanizzati anti-BAG3
BR112017002234A2 (pt) anticorpos anti-pd-l1
TH1601002569A (th) แอนติ-ccl17 แอนติบอดี
TH1601001140A (th) แอนติบอดี
UA27614S (uk) Карбюратор
UA27615S (uk) Карбюратор